Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Cash from Financing Activities came in at -$62000.0 in Q1 2026, down 100.06% YoY from $101.7 million in Q1 2025, and down 150.41% on a QoQ basis from $123000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Cash from Financing Activities data on file, last reported at -$62000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 100.06% year-over-year to -$62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$169000.0 (down 100.17% YoY) and the FY2025 annual result came in at $101.6 million, up 28529.58% from the prior year.
- Cash from Financing Activities retreated to -$62000.0 in Q1 2026, from $123000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $101.7 million in Q1 2025 to a low of -$177000.0 in Q2 2025.
- A 5-year average of $11.2 million and a median of -$1000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 1800.0% — and 2025, when it soared 535584.21%.
- Tracing ALGS's Cash from Financing Activities over 5 years: stood at $121000.0 in 2022, then soared by 72574.38% to $87.9 million in 2023, then plunged by 99.89% to $97000.0 in 2024, then climbed by 26.8% to $123000.0 in 2025, then tumbled by 150.41% to -$62000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$62000.0 (Q1 2026), $123000.0 (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | 220,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220,000.00 |
| Jun 30, 2026 | 220,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Mar 31, 2025 | 101.74 Mn |
| Mar 31, 2025 | 101.74 Mn |
| Dec 31, 2024 | 97,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |